Rare metabolic disorders: cross-border specialty drug access for international patients

Quick orientation

Rare metabolic disorders collectively affect approximately 1 in 1,000 to 1 in 5,000 people depending on classification, but each individual disorder is generally ultra-rare.

Typical age of onset. Most present in infancy or childhood; some have adult-onset variants.

Severity tiers. Severity varies widely by disorder and individual genotype.

Why specialty drugs for Rare metabolic disorders are hard to access internationally

Targeted therapies for specific rare metabolic disorders, including newer FDA approvals for hypophosphatasia, urea cycle disorders, and amino acid metabolism disorders, are not always available locally even in markets with developed healthcare systems.

Treatments approved by the FDA

• Crexont (carbidopa and levodopa, modified release; relevant for adjacent rare-motor-disease care) — FDA approval: 2024. Mechanism: Modified-release dopamine replacement (Parkinson disease label; representative of complex metabolic management). Route: Oral. US WAC ballpark: Approximately USD 15,000 to 25,000 per year. Country pricing: UAE · Saudi Arabia · India · Qatar · Kuwait.
• Voyxact (lonapegsomatropin-tcgd) — FDA approval: 2021. Mechanism: Weekly somatropin for pediatric GHD (representative of adjacent rare-endocrine ERT-style care). Route: Subcutaneous injection weekly. US WAC ballpark: Approximately USD 60,000 to 90,000 per year, weight-based. Country pricing: India · Lebanon.
• Ravicti (glycerol phenylbutyrate) — FDA approval: 2013. Mechanism: Nitrogen-binding agent for urea cycle disorders. Route: Oral with meals. US WAC ballpark: Approximately USD 300,000 to 800,000 per year. Country pricing: UAE · Saudi Arabia · India · Kuwait · Egypt · Jordan.

Cross-border pathways used for Rare metabolic disorders

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Rare Pediatric Disease

What your physician needs to know

• Confirm specific metabolic diagnosis by biochemical and genetic testing.
• Document organ involvement and current functional status.
• Metabolic dietitian co-management is often essential.
• Pediatric metabolic specialist co-management is required.
• Long-term planning for supply continuity and dose escalation as the child grows.

Common questions

Which rare metabolic disorders does Reserve Meds support?

We support those for which FDA-approved targeted therapy exists and cross-border supply is feasible.

Are these drugs available in my country?

Availability varies widely. Many ultra-rare-disorder products have no local supply chain.

How long does shipment take?

Five to fifteen business days for most products.

What documents are required?

Treating specialist's prescription, biochemical and genetic confirmation, and clinical summary.

Can dietary support be coordinated?

We focus on drug supply. Local metabolic dietitian collaboration is recommended.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Rare metabolic disorders, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Rare metabolic disorders

Reserved for you.